Justin J. Watkins

justin.watkins dbr.com
Phone: (215) 988-2593 (215) 988-2593
Fax: (215) 988-2757


Justin J. Watkins advises clients on mergers and acquisitions, venture capital and private equity investment, divestitures, joint ventures and other strategic transactions, and general business counseling. He has represented both public and private companies in corporate transactions in a variety of industries, including manufacturing, pharmaceutical, health care, and health care information technology.

In addition to consulting with clients on corporate transactions, Justin also regularly advises clients on life sciences and intellectual property agreements—including but not limited to clinical trial agreements, research agreements, and complex licensing agreements. He also counsels clients on commercial contracts, corporate governance and other matters relating to business operation and formation.

Prior to beginning his legal career, Justin was the associate director of Intellectual Property at the University of Pennsylvania’s Center for Technology Transfer. He also worked as a research scientist at Taylor Technology, Inc. in Princeton, New Jersey and as a senior research assistant in the Department of Physiology at Amylin Pharmaceuticals, Inc. in San Diego, California.


Justin has significant experience handling mergers and acquisitions. Representative matters include:

  • A privately-held manufacturer of household appliances in its $90 million acquisition of a power cell company;
  • A publicly traded healthcare solutions company in its $225 million acquisition of a specialty pharmaceutical company
  • A private equity fund in its $104 million acquisition of a provider of engineering solutions and high-precision manufacturing capabilities
  • A private equity fund in its acquisitions of a number of medical tubing extruding companies for aggregate consideration of over $29 million

Justin has handled many venture investing matters for his clients, including:

  • A privately-held manufacturer of household appliances in its $17 million Series C investment in a power cell company
  • A biotechnology venture fund in its $6 million Series AA investment in a privately held pharmaceutical company
  • A private equity fund in connection with several investments in portfolio companies, including acquisition, debt financing and capital structure matters
  • The venture arm of a Fortune 50 pharmaceutical company in connection with a $17 million convertible preferred stock investment in a healthcare IT company

Here is a sampling of Justin's representative matters involving life science transactions:

  • A publicly traded healthcare solutions company in a strategic partnering transaction with a publicly-traded biotechnology company, which included components of research and development, intellectual property licensing, and product manufacture and supply
  • A publicly traded pharmaceutical company in its negotiation of all clinical trial agreements in the U.S. in connection with a Phase III clinical trial for a novel small molecule therapeutic


Bar Admissions

  • Pennsylvania


  • Temple University Beasley School of Law, J.D., 2005, cum laude
  • Swarthmore College, B.A., 1993


  • American Bar Association
  • Licensing Executives Society
  • Pennsylvania Bar Association
  • Pennsylvania Biotechnology Association (BIO)